Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 251 | 3.71 |
09:54 ET | 100 | 3.85 |
09:57 ET | 300 | 3.68 |
10:01 ET | 2600 | 3.68 |
10:03 ET | 100 | 3.68 |
10:32 ET | 100 | 3.64 |
11:15 ET | 1813 | 3.6 |
11:42 ET | 400 | 3.66 |
12:16 ET | 566 | 3.69 |
12:21 ET | 100 | 3.62 |
12:41 ET | 200 | 3.61 |
12:52 ET | 200 | 3.64 |
12:54 ET | 300 | 3.64 |
12:56 ET | 200 | 3.68 |
12:59 ET | 200 | 3.68 |
01:03 ET | 1466 | 3.64 |
01:19 ET | 100 | 3.68 |
01:30 ET | 100 | 3.68 |
01:33 ET | 100 | 3.7 |
01:35 ET | 100 | 3.7 |
01:50 ET | 100 | 3.7 |
02:04 ET | 100 | 3.69 |
02:06 ET | 300 | 3.7 |
02:08 ET | 100 | 3.73 |
02:33 ET | 100 | 3.61 |
02:42 ET | 230 | 3.685 |
02:44 ET | 100 | 3.65 |
02:47 ET | 100 | 3.68 |
03:09 ET | 238 | 3.63 |
03:16 ET | 100 | 3.65 |
03:27 ET | 200 | 3.65 |
03:30 ET | 200 | 3.66 |
03:32 ET | 200 | 3.66 |
03:34 ET | 100 | 3.66 |
03:36 ET | 100 | 3.675 |
03:41 ET | 287 | 3.63 |
03:43 ET | 100 | 3.635 |
03:48 ET | 200 | 3.65 |
03:52 ET | 6415 | 3.83 |
03:54 ET | 2474 | 3.88 |
03:56 ET | 6024 | 3.65 |
03:57 ET | 400 | 3.78 |
03:59 ET | 1006 | 3.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 209.3M | -2.0x | --- |
Trevi Therapeutics Inc | 209.9M | -8.8x | --- |
Eliem Therapeutics Inc | 206.8M | -13.3x | --- |
Gossamer Bio Inc | 203.8M | -0.9x | --- |
Inovio Pharmaceuticals Inc | 209.4M | -1.5x | --- |
Fractyl Health Inc | 204.5M | -2.5x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $209.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-1.88 |
Book Value | $5.64 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.